Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Harmony Biosciences' ( NASDAQ: HRMY) stock fell about 7.3% after U.S. FDA notified the company that it will not review the ...

Harmony Biosciences currently markets pitolisant as WAKIX® in the U.S. for the treatment of EDS or cataplexy in adult patients with narcolepsy and for EDS in pediatric patients 6 years of age and ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 10,550,000 shares, a ...

Nations Financial Group Inc. IA ADV acquired a new position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & ...

Avadel Pharmaceuticals' stock is undervalued due to peak sales potential, along with the possibility of a buyout. Click here ...

Operator Good morning, and welcome to the Axsome Therapeutics fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a ...

An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for ...

Read on for her answers to frequently asked questions about managing sleep attacks. Cataplexy is the least common symptom of these, and many people with narcolepsy never experience it. Narcolepsy ...

In the same 2020 study, researchers found that: 66% of participants with narcolepsy reported falling asleep while driving 29% experienced cataplexy while driving 12% experienced sleep paralysis ...

Avadel’s commercial product, LUMRYZ TM, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients ...